Progenics Pharmaceuticals (NASDAQ:PGNX) Receives News Impact Score of 0.15

News coverage about Progenics Pharmaceuticals (NASDAQ:PGNX) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.3006237050057 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

NASDAQ:PGNX traded down $0.02 during trading hours on Friday, hitting $7.32. 588,645 shares of the company’s stock traded hands, compared to its average volume of 1,368,124. The firm has a market capitalization of $533.34, a price-to-earnings ratio of -8.13 and a beta of 2.46. Progenics Pharmaceuticals has a 52 week low of $4.60 and a 52 week high of $8.63. The company has a debt-to-equity ratio of 0.74, a quick ratio of 6.31 and a current ratio of 6.31.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.21). The company had revenue of $3.90 million during the quarter, compared to analyst estimates of $3.18 million. Progenics Pharmaceuticals had a negative return on equity of 87.30% and a negative net margin of 436.08%. The firm’s quarterly revenue was down 15.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.10) earnings per share. equities analysts forecast that Progenics Pharmaceuticals will post -0.8 earnings per share for the current fiscal year.

PGNX has been the subject of a number of analyst reports. Cantor Fitzgerald set a $15.00 price target on Progenics Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, January 2nd. BidaskClub raised Progenics Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research raised Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a report on Thursday, January 4th. Finally, ValuEngine lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, three have given a buy rating and two have given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $12.35.

COPYRIGHT VIOLATION NOTICE: “Progenics Pharmaceuticals (NASDAQ:PGNX) Receives News Impact Score of 0.15” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Insider Buying and Selling by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply